News & Insights
Find the latest updates, news and insights from across BAP Pharma’s expert teams.
September 18, 2026
Download the full guide For families, caregivers and healthcare professionals looking to understand Early Access Programs in more detail, the full guide...
August 6, 2026
From the outside, a Managed Access Program can look deceptively simple. A patient needs treatment. A physician makes a request. Medicine is...
July 20, 2026
For years, Rare Disease Access has been defined by three critical questions: Does a treatment exist? Is it approved? Will it be...
July 20, 2026
Across the life sciences industry, there is growing pressure to accelerate the path from development to patient access. Faster IND approvals, streamlined...
May 18, 2026
In complex clinical trials, packaging and labelling are often treated as necessary executional steps — but secondary. In reality, they are critical...
May 15, 2026
The Challenge A leading BAP Pharma client required urgent local sourcing in China for a decentralised clinical study in immunology. The immediate...
May 14, 2026
The Challenge A critical Phase III cardiovascular trial restart was placed at immediate risk when a previous supplier failed to deliver six...
May 13, 2026
In multi-country clinical trials, labelling complexity increases rapidly. Different regulatory requirements, language variations, and country-specific interpretations all converge at a single point:...
May 6, 2026
The Ehlers-Danlos Society – Why are people with EDS and HSD receiving such late access to innovative therapies? What is Ehlers-Danlos syndrome...